Wells Fargo initiated coverage of Summit Therapeutics (SMMT) with an Overweight rating and $30 price target The firm says its deep dive on the PD1/VEGF space puts Summit Therapeutics as a front-runner in grabbing a big chunk of the $100B opportunity. News flow over the next 12-18 months should provide further upside, Wells adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics initiated with a Buy at Jefferies
- Biotech Alert: Searches spiking for these stocks today
- TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks for the Rest of 2024
- Summit Therapeutics initiated with an Outperform at JMP Securities
- Summit Therapeutics price target lowered to $44 from $45 at H.C. Wainwright